Pancreatic cancer model with in vivo imaging and therapeutic trial
Project/Area Number |
23591908
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Nippon Medical School |
Principal Investigator |
UCHIDA EIJI 日本医科大学, 医学(系)研究科(研究院), 教授 (70176684)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Keywords | 膵癌 / 実験モデル / イメージング / 治療実験 / 実験膵癌 / PGHAM-1 / gemcitabine / IVIS system |
Research Abstract |
We established several pancreatic cancer models using hamster pancreatic cancer cell line, PGHAM-1. PGHAM-1 cells with luciferase activity transduced by viral vectors (PGHAM-1-Luc) ware used for in vivo imaging of cancer proliferation and metastasis using IVIS system by measuring the bioluminescent signals. Using this system, the effect of gemcitabine on pancreatic cancer model was investigated in vitro and in vivo. Anti-tumor effect of gemcitabine was found in vitro but not in vivo by using IVIS system quantitative analysis. This cancer model is suitable for detecting the new therapeutic agents, although improved in vivo imaging system and its application are needed in the near future.
|
Report
(4 results)
Research Products
(56 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Sno/SKL modulates proliferation through control of hsa-miR-720 transcription in esophageal cancer cells2013
Author(s)
Shinozuka E, Miyashita M, Mizuguchi Y, Akagi I, Kikuchi K, Makino H, Matsutani T, Hagiwara N, Momura T, Uchida E, Takizawa T.
-
Journal Title
Biochem Biomed Res Com
Volume: 430
Pages: 101-106
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-